Research Information System
The 62nd Annual ESPE Meeting 2024, Liverpool, England, 16 - 18 October 2024, pp.368, (Summary Text)
Objective: As obesity rates rise among children, non-alcholic fatty liver disease (NAFLD) is becoming more prevalent. Although liver biopsy is considered the gold standard for diagnosing NAFLD, it is an invasive procedure and not practical for screening. Asprosin, a recently unveiled adipokine, is released in response to fasting. In this study, we aim ed to investigate the diagnostic value of asprosin for NAFLD in obese patients.
Methods: A total of 142 participants (71 obese, 71 control) aged between 6 and 18 years were included in the study. Obese patients were also divided to subgroup as NAFLD (+) and NAFLD (-) according to hepatobilier ultrasonopgraphic features and compared with eachother regarding their clinical and laboratory features including asprosin level.
Results: When comparing obese and non-obese patients, asprosin levels were significantly higher in the obese group (P = 0.034). NAFLD was diagnosed in 35 (49.2%) of the obese cases. While BMI were similar; waist circumference and insulin resistance were higher in patients with NAFLD. When comparing Asprosin, interleukine-6 (IL-6), and tumor necrosing factor alpha (TNF-α) levels, no statistically significant differences were observed between the NAFLD(+) and NAFLD(-) subgroups. The level of Asprosin showed a positive correlation with IL-6 and TNF-α levels, while no significant relationship was found between the asprosin and any clinical or laboratory parameters in obese patients with NAFLD.
Conclusion: Serum asprosin levels were elevated in obese children. However, there were no significant findings to support the use of asprosin levels as a non-traumatic diagnostic indicator for NAFLD diagnosis in the pediatric age.